Full Breakdown
Trump Administration Accelerates AI Integration into U.S. Medical Care
By Drooid · · How we work
Core Push for AI-Driven Diagnosis and Treatment
The Department of Health and Human Services is directing federal resources toward deploying artificial-intelligence agents that can diagnose patients and prescribe medicines. A new Medicare payment category is being drafted to reimburse companies that supply such AI software, extending the program that already covers more than 200 pilot projects. The effort is framed as a way to improve outcomes and lower costs for the roughly 60 million Medicare beneficiaries.
Background and Policy Landscape
The Food and Drug Administration has approved over 1,500 medical devices that use AI for specific tasks such as tumor detection, but it lacks a regulatory framework for fully autonomous AI that functions like a physician. One pilot, the “Hope” chatbot from Limbic, offers talk-therapy to Medicare beneficiaries with anxiety or depression, while the Advanced Research Projects Agency for Health (ARPA-H) backs “Advocate,” an AI system intended to manage heart-failure care, including medication adjustments. Critics note that Silicon Valley investors—most prominently venture capitalist Vinod Khosla—have gained unprecedented influence over these initiatives.
Official Statements & Responses
He promoted his son’s company, Curai Health, as a rapid-access primary-care solution and said CMS appears “very excited.” Health Secretary Robert F. Kennedy Jr. acknowledged the risk that AI could “go rogue” but maintained that the technology could revolutionize medicine. Deputy Commissioner for Technology and Artificial Intelligence Jared Seehafer, newly appointed, is reported to favor reduced agency oversight of medical AI, a stance that has sparked internal clashes with career staff such as Dr. Michelle Tarver, who urges expert-scientist leadership for safety reviews.
Verbatim Quotes
- “C.M.S. seems to be very excited,” — Mr. Khosla — Mr. Khosla